The ENHANCE study demonstrated that 30-minute infusions of BRIUMVI were well tolerated, with only mild infusion-related reactions (Grade 1). How impactful is this shortened infusion time for patient care, particularly in enhancing convenience for those living with RMS?

The study supports the elimination of the initial 150 mg BRIUMVI infusion for patients switching from a prior anti-CD20 therapy while in a B-cell depleted state. Could you discuss the clinical significance of this finding and its potential to streamline the treatment process for transitioning patients?

With infusion-related reactions being mild and resolving completely, how do these results compare to other CD20 therapies in terms of tolerability? Could this improved safety profile make BRIUMVI a more favorable option for long-term RMS management?

Given that these rapid infusions eliminate the need for post-infusion observation time, how might this influence patients’ overall treatment experience and adherence, especially those balancing treatment with their daily lives?

The ability to administer 450 mg BRIUMVI in just 30 minutes without major infusion interruptions could increase access to treatment in more settings. How do you foresee this influencing the accessibility of high-efficacy MS treatments in outpatient or even community clinic environments?

BRIUMVI has shown to effectively deplete B-cells, a key factor in MS progression. Do these updated findings provide any insights into the durability of its therapeutic effects, particularly in maintaining long-term disease control for patients with relapsing forms of MS?

Given the promising data on shortened infusion times, what are the next steps for TG Therapeutics in terms of seeking regulatory approval to include rapid infusion protocols in BRIUMVI's labeling? How significant could these changes be for the treatment landscape?

Looking ahead, what do you see as the future role of BRIUMVI in RMS treatment? Could further optimization of its dosing or infusion protocols position it as a first-line therapy for relapsing MS, especially in light of evolving patient needs for faster and more convenient treatments?